Image-guided radiotherapy: From current concept to future perspectives

Nature Reviews Clinical Oncology

Volumn 9, Issue 12, 2012, Pages 688-699

  Jaffray, David A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18;

ACCURACY; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE GUIDED RADIOTHERAPY; IMAGE QUALITY; LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIATION DOSE REDUCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC DEVICE; TOMOTHERAPY; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ANIMALS; HUMANS; NEOPLASMS; RADIOTHERAPY, IMAGE-GUIDED;

EID: 84870454408     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.194     Document Type: Review

References (102)

1. Moller, T. R., Einhorn, N., Lindholm, C., Ringborg, U. & Svensson, H. Radiotherapy and cancer care in Sweden. Acta Oncol. 42, 366-375 (2003).
2. Delaney, G., Jacob, S., Featherstone, C. & Barton, M. The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104, 1129-1137 (2005).
3. Brahme, A. Dosimetric requirements in radiation therapy. Acta Radiol. Oncol. 23, 379 (1984).
4. Hendee, W. R. & Herman, M. G. Improving patient safety in radiation oncology. Med. Phys. 38, 78-82 (2011).
5. ICRU50. ICRU report 50: Prescribing, recording, and reporting photon beam therapy (International Commission on Radiation Units & Measurements, Bethesda, MD, 1993).
6. ICRU62. ICRU report 62: Prescribing, recording, reporting photon beam therapy (Suppl. to ICRU 50) (International Commission on Radiation Units & Measurements, Bethesda, MD, 1999).
7. ICRU83. ICRU report 83: Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). 10 (2010).
8. Simpson, D. R. et al. A survey of image-guided radiation therapy use in the United States. Cancer 116, 3953-3960 (2010).
9. Molloy, J. A. et al. Quality assurance of U. S.-guided external beam radiotherapy for prostate cancer: Report of AAPM Task Group 154. Med. Phys. 38, 857-871 (2011).
10. Keall, P. J. et al. The management of respiratory motion in radiation oncology report of AAPM Task Group 76. Med. Phys. 33, 3874-3900 (2006).
11. Langen, K. M. & Jones, D. T. Organ motion and its management. Int. J. Radiat. Oncol. Biol. Phys. 50, 265-278 (2001).
12. Millender, L. E., Aubin, M., Pouliot, J., Shinohara, K. & Roach, M. 3rd. Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 59, 6-10 (2004).
13. Keall, P. J. et al. The management of respiratory motion in radiation oncology report of AAPM Task Group 76. Med. Phys. 33, 3874-3900 (2006).
14. Wolthaus, J. W. et al. Comparison of different strategies to use four-dimensional computed tomography in treatment planning for lung cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 70, 1229-1238 (2008).
15. Korreman, S., Persson, G., Nygaard, D., Brink, C. & Juhler-Nottrup, T. Respiration-correlated image guidance is the most important radiotherapy motion management strategy for most lung cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 83, 1338-1343 (2012).
16. Moseley, D. J. et al. Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 67, 942-953 (2007).
17. Kupelian, P. A. et al. Daily variations in delivered doses in patients treated with radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 66, 876-882 (2006).
18. Kupelian, P. A. et al. Evaluation of image-guidance strategies in the treatment of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70, 1151-1157 (2008).
19. ASRT Foundation. Radiation Therapy, Management and Dosimetry Workplace Survey [online], http://www.asrtfoundation.org/Media/pdf/HCIAC/R10/ RadTherReport.pdf (2010).
20. Zelefsky, M. J. et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 84, 125-129 (2012).
21. Bissonnette, J. P. & Medlam, G. Trend analysis of radiation therapy incidents over seven years. Radiother. Oncol. 96, 139-144 (2010).
22. Peters, L. J. et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: Results from TROG 02.02. J. Clin. Oncol. 28, 2996-3001 (2010).
23. van Herk, M. Errors and margins in radiotherapy. Semin. Radiat. Oncol. 14, 52-64 (2004).
24. Den, R. B. et al. Daily image guidance with cone-beam computed tomography for headandneck cancer intensity-modulated radiotherapy: A prospective study. Int. J. Radiat. Oncol. Biol. Phys. 76, 1353-1359 (2010).
25. Nutting, C. M. et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial. Lancet Oncol. 12, 127-136 (2011).
26. Chen, A. M. et al. Evaluation of the planning target volume in the treatment of head and neck cancer with intensity-modulated radiotherapy: What is the appropriate expansion margin in the setting of daily image guidance? Int. J. Radiat. Oncol. Biol. Phys. 81, 943-949 (2011).
27. Crehange, G. et al. Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer. Radiother. Oncol. 103, 244-246 (2012).
28. Engels, B., Soete, G., Verellen, D. & Storme, G. Conformal arc radiotherapy for prostate cancer: Increased biochemical failure in patients with distended rectum on the planning computed tomogram despite image guidance by implanted markers. Int. J. Radiat. Oncol. Biol. Phys. 74, 388-391 (2009).
29. Potters, L. et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guidelines for image-guided radiation therapy (IGRT). Int. J. Radiat. Oncol. Biol. Phys. 76, 319-325 (2010).
30. Pollack, A. et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 53, 1097-1105 (2002).
31. Epp, E. R. & Suit, H. D. The need for on-line portal images of diagnostic xray quality from linear accelerators. Int. J. Radiat. Oncol. Biol. Phys. 30, 495-496 (1994).
32. Martin, J. M. et al. Image guided dose escalated prostate radiotherapy: Still room to improve. Radiat. Oncol. 4, 50 (2009).
33. Timmerman, R. et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303, 1070-1076 (2010).
34. Greco, C. et al. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int. J. Radiat. Oncol. Biol. Phys. 79, 1151-1157 (2011).
35. Lee, M. T. et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J. Clin. Oncol. 27, 1585-1591 (2009).
36. Hall, E. & Giacca, A. J. Radiobiology for the Radiologist (Lippincott, Williams & Wilkins, Philidelphia, 2006).
37. Brenner, D. J. & Hall, E. J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 43, 1095-1101 (1999).
38. Garcia-Barros, M. et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1159 (2003).
39. Lee, Y. et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment. Blood 114, 589-595 (2009).
40. Wong, R. K. et al. A one-step cone-beam CTenabled planningtotreatment model for palliative radiotherapy-from development to implementation. Int. J. Radiat. Oncol. Biol. Phys. 84, 834-440 (2012).
41. Ling, C. C. et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int. J. Radiat. Oncol. Biol. Phys. 47, 551-560 (2000).
42. Lambin, P. et al. The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: Exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiother. Oncol. 96, 145-152 (2010).
43. Gregoire, V., Haustermans, K., Geets, X., Roels, S. & Lonneux, M. PET-based treatment planning in radiotherapy: A new standard? J. Nucl. Med. 48 (Suppl. 1), 68S-77S (2007).
44. Moman, M. R. et al. Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences. Int. J. Radiat. Oncol. Biol. Phys. 76, 741-746 (2010).
45. Daisne, J. F. et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: Comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233, 93-100 (2004).
46. Lockhart, C. M. et al. Quantifying and reducing the effect of calibration error on variability of PET/CT standardized uptake value measurements. J. Nucl. Med. 52, 218-224 (2011).
47. Nehmeh, S. A. et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 70, 235-242 (2008).
48. Christian, N. et al. The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. Radiother. Oncol. 91, 101-106 (2009).
49. Bowen, S. R., Flynn, R. T., Bentzen, S. M. & Jeraj, R. On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. Phys. Med. Biol. 54, 1483-1501 (2009).
50. de Geus-Oei, L. F. et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J. Nucl. Med. 48, 1592-1598 (2007).
51. van Baardwijk, A. et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother. Oncol. 82, 145-152 (2007).
52. Eschmann, S. M. et al. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 55, 165-171 (2007).
53. Aerts, H. J. et al. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDGPETCT scan: A prospective validation. Lung Cancer 75, 73-76 (2012).
54. Yan, D., Vicini, F., Wong, J. & Martinez, A. Adaptive radiation therapy. Phys. Med. Biol. 42, 123-132 (1997).
55. Siker, M. L., Tome, W. A. & Mehta, M. P. Tumor volume changes on serial imaging with megavoltage CT for nonsmallcell lung cancer during intensity-modulated radiotherapy: How reliable, consistent, and meaningful is the effect? Int. J. Radiat. Oncol. Biol. Phys. 66, 135-141 (2006).
56. Barker, J. L. Jr et al. Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for headandneck cancer using an integrated CT/linear accelerator system. Int. J. Radiat. Oncol. Biol. Phys. 59, 960-970 (2004).
57. Mayr, N. A. et al. Translating response during therapy into ultimate treatment outcome: A personalized 4dimensional MRI tumor volumetric regression approach in cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 76, 719-727 (2010).
58. Martinez, A. A. et al. Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 50, 1226-1234 (2001).
59. Gospodarowicz, M & O'Sullivan, B. Prognostic Factors in Oncology (UICC, Geneva, Switzerland, 2003).
60. Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727-1733 (1979).
61. Schwartz, D. L. et al. Adaptive radiotherapy for headandneck cancer: Initial clinical outcomes from a prospective trial. Int. J. Radiat. Oncol. Biol. Phys. 83, 986-993 (2012).
62. Brabbins, D. et al. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: Analysis of chronic toxicity. Int. J. Radiat. Oncol. Biol. Phys. 61, 400-408 (2005).
63. Stewart, J. M. P. et al. Automated weekly online replanning for IMRT of cervix cancer. Int. J. Radiat. Oncol. Biol. Phys. 72, S18 (2008).
64. Lim, K. et al. Pelvic radiotherapy for cancer of the cervix: Is what you plan actually what you deliver? Int. J. Radiat. Oncol. Biol. Phys. 74, 304-312 (2009).
65. Potter, R. et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother. Oncol. 83, 148-155 (2007).
66. Guckenberger, M., Richter, A., Wilbert, J., Flentje, M. & Partridge, M. Adaptive radiotherapy for locally advanced nonsmallcell lung cancer does not underdose the microscopic disease and has the potential to increase tumor control. Int. J. Radiat. Oncol. Biol. Phys. 81, e275-e282 (2012).
67. Yan, D. Adaptive radiotherapy: Merging principle into clinical practice. Semin. Radiat. Oncol. 20, 79-83 (2010).
68. Purdie, T. G., Dinniwell, R. E., Letourneau, D., Hill, C. & Sharpe, M. B. Automated planning of tangential breast intensity-modulated radiotherapy using heuristic optimization. Int. J. Radiat. Oncol. Biol. Phys. 81, 575-583 (2011).
69. Raaymakers, B. W. et al. Integrating a 1.5 T MRI scanner with a 6 MV accelerator: Proof of concept. Phys. Med. Biol. 54, N229-N237 (2009).
70. Fallone, B. G. et al. First MR images obtained during megavoltage photon irradiation from a prototype integrated linac-MR system. Med. Phys. 36, 2084-2088 (2009).
71. Karlsson, M., Karlsson, M. G., Nyholm, T., Amies, C. & Zackrisson, B. Dedicated magnetic resonance imaging in the radiotherapy clinic. Int. J. Radiat. Oncol. Biol. Phys. 74, 644-651 (2009).
72. Moffat, B. A. et al. Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc. Natl Acad. Sci. USA 102, 5524-5529 (2005).
73. Jaffray, D. A., Carlone, M., Menard, C. & Breen, S. in Society of Photo-Optical Instrumentation and Engineering (SPIE) Vol. 7622 (Eds Samei, E. & Pelc, N. J.) 762202-762202-12 (San Diego, CA, 2010).
74. Raaymakers, B. W., Raaijmakers, A. J. & Lagendijk, J. J. Feasibility of MRI guided proton therapy: Magnetic field dose effects. Phys. Med. Biol. 53, 5615-5622 (2008).
75. Wei, Z. et al. Robot-assisted 3D-TRUS guided prostate brachytherapy: System integration and validation. Med. Phys. 31, 539-548 (2004).
76. Yan, D., Jaffray, D. A. & Wong, J. W. A model to accumulate fractionated dose in a deforming organ. Int. J. Radiat. Oncol. Biol. Phys. 44, 665-675 (1999).
77. Brock, K. K., Sharpe, M. B., Dawson, L. A., Kim, S. M. & Jaffray, D. A. Accuracy of finite element model-based multi-organ deformable image registration. Med. Phys. 32, 1647-1659 (2005).
78. Jaffray, D. A., Lindsay, P. E., Brock, K. K., Deasy, J. O. & Tome, W. A. Accurate accumulation of dose for improved understanding of radiation effects in normal tissue. Int. J. Radiat. Oncol. Biol. Phys. 76, S135-S139 (2010).
79. Paganetti, H. Range uncertainties in proton therapy and the role of Monte Carlo simulations. Phys. Med. Biol. 57, R99-R117 (2012).
80. Letourneau, D. et al. Semiautomatic vertebrae visualization, detection, and identification for online palliative radiotherapy of bone metastases of the spine. Med. Phys. 35, 367-376 (2008).
81. Lambrecht, M. et al. The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer. Acta Oncol. 49, 956-963 (2010).
82. Zhang, C. et al. 18FFDGPET evaluation of treatment response to neo-adjuvant therapy in patients with locally advanced rectal cancer: A meta-analysis. Int. J. Cancer 131, 2604-2611 (2012).
83. Edet-Sanson, A. et al. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC). Radiother. Oncol. 102, 251-257 (2012).
84. Souhami, L. et al. Weekly cisplatin plus external beam radiotherapy and high dose rate brachytherapy in patients with locally advanced carcinoma of the cervix. Int. J. Radiat. Oncol. Biol. Phys. 27, 871-878 (1993).
85. Lim, K. et al. Cervical cancer regression measured using weekly magnetic resonance imaging during fractionated radiotherapy: Radiobiologic modeling and correlation with tumor hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 70, 126-133 (2008).
86. Stewart, J. et al. Automated weekly replanning for intensity-modulated radiotherapy of cervix cancer. Int. J. Radiat. Oncol. Biol. Phys. 78, 350-358 (2010).
87. Mayr, N. A. et al. Ultra-early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer. Cancer 116, 903-912 (2010).
88. Ang, K. K. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363, 24-35 (2010).
89. Voduc, K. D. et al. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 28, 1684-1691 (2010).
90. Shi, W. W. et al. Post-menopausal women with luminal A subtype might not require breast radiotherapy: Preliminary results from a randomized clinical trial of tamoxifen + radiation [abstract]. Cancer Res. 72, a1032 (2012).
91. Griffin, A. M. et al. Radiation planning comparison for superficial tissue avoidance in radiotherapy for soft tissue sarcoma of the lower extremity. Int. J. Radiat. Oncol. Biol. Phys. 67, 847-856 (2007).
92. O'Sullivan, B. et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial. Lancet 359, 2235-2241 (2002).
93. Rieke, V. & Butts Pauly, K. MR thermometry. J. Magn. Reson. Imaging 27, 376-390 (2008).
94. de Smet, M., Heijman, E., Langereis, S., Hijnen, N. M. & Grull, H. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: An in vivo proofofconcept study. J. Control Release 150, 102-110 (2011).
95. Czarnota, G. J. et al. Tumor radiation response enhancement by acoustical stimulation of the vasculature. Proc. Natl Acad. Sci. USA 109, E2033-E2041 (2012).
96. Eisbruch, A. et al. Dysphagia and aspiration after chemoradiotherapy for headandneck cancer: Which anatomic structures are affected and can they be spared by IMRT? Int. J. Radiat. Oncol. Biol. Phys. 60, 1425-1439 (2004).
97. O'Daniel, J. C. et al. Parotid gland dose in intensity-modulated radiotherapy for head and neck cancer: Is what you plan what you get? Int. J. Radiat. Oncol. Biol. Phys. 69, 1290-1296 (2007).
98. Greco, C. et al. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int. J. Radiat. Oncol. Biol. Phys. 79, 1151-1157 (2011).
99. Lin, Z. et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int. J. Radiat. Oncol. Biol. Phys. 70, 1219-1228 (2008).
100. Pouliot, J. et al. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int. J. Radiat. Oncol. Biol. Phys. 59, 1196-1207 (2004).
101. Aerts, H. J. et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18FluorodeoxyglucosePETCT scan. Radiother. Oncol. 91, 386-392 (2009).
102. Ghilezan, M., Yan, D. & Martinez, A. Adaptive radiation therapy for prostate cancer. Semin. Radiat. Oncol. 20, 130-137 (2010).